글로벌 이종줄기세포 치료 시장 – 2030년까지의 산업 동향 및 예측

 동종 줄기 세포 치료 시장 분석 및 규모

과학자들은 줄기 세포가 뼈, 심혈관계, 신경 종말 및 기타 장기와 조직의 세포로 발달하는 것을 관찰함으로써 질병과 장애가 어떻게 발달하는지 더 잘 이해할 수 있습니다. 줄기 세포는 이식 및 유전자 조작을 위해 새로운 조직으로 성장할 수 있습니다. 연구자들은 줄기 세포와 재생 ​​의학에서의 응용 분야에 대해 계속해서 더 많이 배우고 있으며, 이는 2023-2030년의 예측 기간 동안 시장 성장을 주도할 것입니다.

Data Bridge Market Research는 2022년에 9억 9,490만 달러였던 이종 줄기세포 치료 시장이 2030년까지 21억 9,500만 달러에 도달할 것으로 분석했으며, 2023년부터 2030년까지의 예측 기간 동안 연평균 성장률은 9.85%에 이를 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

동종 줄기 세포 치료 시장 범위 및 세분화

Market Definition

Stem cell therapy, also known as regenerative medicine, uses stem cells or their derivatives to promote the repair response of dysfunctional,diseased, or injured tissue. Stem cells can develop into various types of cells in the body. Pluripotent and multipotent stem cells are the two main types of stem cells. Pluripotent stem cells are replicating cells that develop from embryonic or fetal tissues. Pluripotent stem cells help the cells and tissues develop in three primary germ layers: mesoderm, ectoderm, and endoderm.

Global Allogenic Stem Cell Therapy Market Dynamics

Drivers

• Increasing funding for stem cell research projects

The need for newer and better therapies for auto-immune, neurobiological, and coronary heart disease treatment has increased cumulative research activities and funding for cell-based research. For instance, the University of Sydney was awarded $6.3 million in June 2021 for three projects addressing adult vision loss and cardiovascular events and improving decisions about access to stem cell interventions. In the same year, Stanford physician-researchers were awarded nearly $31 million by the California Institute for Regenerative Medicine to begin first-in-human trials of stem therapies for treating stroke, heart failure, and a type of brain and spinal cord tumor. These are certain factors that propel the growth of the market.

• Rising number of launches

Increased product launches by key market players are expected to drive the market during the forecast period. For instance, LifeCell, a healthcare service provider, introduced an advanced umbilical cord-stem cell collection kit in August 2017 that protects neonatal stem cells from environmental damage and temperature fluctuations.

Opportunities

• Potential of stem cells for drug discovery

The ability to continuously develop functioning adult tissues in culture using directed differentiation opens up new avenues for drug discovery. Before conducting in vivo trials, researchers can create distinct cell lines and then test novel medications on each cell type in vitro to identify potential interactions. This is critical in developing medicines for use in veterinary research because of the possibility of species-specific combinations. The goal is to having the cell lines available for research use that will reduce the need for research animals because in vitro effects on human tissue will provide insight not previously known before the animal testing phase. These all are the factors which are expected to boost the market growth.

Restraints/Challenges

• Limited awareness regarding treatment

The main factors impeding the growth of the global allogenic stem cell therapy market are a lack of awareness about treatment options and ethical concerns about embryonic stem cells. For instance, according to data published by the National Center for Biotechnology Information, the main factor is the population's fear of unknown therapies and lack of awareness about treatment options. Furthermore, the high cost of the therapies leads to lower adoption, resulting in lower demand for the product globally.

This allogenic stem cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the allogenic stem cell therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Allogenic Stem Cell Therapy Market

The COVID-19 pandemic had a negative impact on the global allogenic stem cell therapy market due to a decrease in stem cell therapy research and development. The COVID-19 pandemic has caused significant disruption in research, manufacturing, and clinical development, according to the National Center for Biotechnology Information. Clinical trial disruption will erode the quality of clinical evidence for CGTs further, making a reliable HTA on the treatment benefits and economic impacts of CGTs even more difficult.

Furthermore, the current situation of COVID-19 is driving the growth of the market, as research activities for COVID-19 treatment are proceeding. Stem cell therapy may also be a promising treatment option for COVID-19 in the future. For instance, Lineage Cell Therapeutics, received a USD 5 million grant from the California Institute for Regenerative Medicine (CIRM) on May 6, 2020, to support the use of VAC, Lineage's allogeneic dendritic cell therapy, in the development of a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.

Recent developments

• In December 2021, Century Therapeutics, a biotechnology company, collaborated with Bristol Myers Squibb, a pharmaceutical company, and signed a licence agreement to develop and commercialise up to four induced pluripotent stem cell ("iPSC") derived, engineered natural killer cell ("iNK") and T cell ("iT") programmes for hematologic malignancies and solid tumors.

Global Allogenic Stem Cell Therapy Market Scope

The allogenic stem cell therapy market is segmented on the basis of product type, cell source, application and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Adult Stem Cells
• Human Embryonic Stem Cells
• Induced Pluripotent Stem Cells

 Cell Source

• Adipose Tissue-Derived Mesenchymal Stem Cells
• Bone Marrow-Derived Mesenchymal Stem Cells
• Cord Blood/Embryonic Stem Cells
• Others

 Applications

• Musculoskeletal Disorders
• Wounds
• Injuries
• Cardiovascular Diseases
• Surgeries
• Gastrointestinal Diseases
• Other

 End Users

• Therapeutic Companies
• Cell and Tissues Banks
• Tools and Reagent Companies
• Service Companies

Allogenic Stem Cell Therapy Market Regional Analysis/Insights

The allogenic stem cell therapy market is analysed and market size insights and trends are provided by country, product type, cell source, application and end users as referenced above.

The countries covered in the allogenic stem cell therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the allogenic stem cell therapy market due to the improved investment scenario, technological advancements, and high economic growth.

Asia-Pacific is expected to grow at the highest growth rate from 2023 to 2030, owing to the surge in the prevalence of target chronic diseases.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

의료 인프라 성장 설치 기반 및 신기술 침투

이종 줄기세포 치료 시장은 또한 모든 국가에 대한 자세한 시장 분석을 제공합니다. 자본 장비에 대한 의료 지출 증가, 이종 줄기세포 치료 시장을 위한 다양한 종류의 제품 설치 기반, 생명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 이종 줄기세포 치료 시장에 미치는 영향. 이 데이터는 2011-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 동종 줄기 세포 치료 시장 점유율 분석

이종 줄기세포 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 이종 줄기세포 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

동종줄기세포 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• • Athersys Inc. (미국)
• • 메소블라스트 유한회사(호주)
• • 바이오레스트러티브 테라피 주식회사 (미국)
• • Pluristem Inc. (이스라엘)
• • 브레인스톰 셀 리미티드(미국)
• • ViaCyte Inc. (미국)
• • 가미다 셀(미국)
• • HOPE BIOSCIENCES (미국)
• • 세포생물의학그룹(미국)
• • 스미스+네퓨(영국)
• • MEDIPOST(한국)
• • ANTEROGEN.CO, LTD. (한국)
• • NuVasive Inc. (미국)
• • RTI 수술(미국)
• • 알로소스(미국)
• • JCR Pharmaceuticals Co. Ltd. (일본)
• • 다케다제약 주식회사(일본) 

SKU-56872